NEVRO CORP.
NVRO
NVRO was delisted on the 2nd of April, 2025.
182 hedge funds and large institutions have $3.38B invested in NEVRO CORP. in 2020 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 67 increasing their positions, 65 reducing their positions, and 37 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 65
5% less funds holding
Funds holding: 191 → 182 (-9)
11% less capital invested
Capital invested by funds: $3.81B → $3.38B (-$434M)
16% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 37
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
33% less call options, than puts
Call options by funds: $23.2M | Put options by funds: $34.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$238M |
| 2 |
HM
HealthCor Management
New York
|
+$70.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$54.9M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$49.5M |
| 5 |
PA
Perceptive Advisors
New York
|
+$39.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$67.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$64.7M |
| 3 |
D.E. Shaw & Co
New York
|
-$52.6M |
| 4 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$51.8M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$28M |
NVRO Hedge Fund Activity: Q1 2020 in Review
182 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in NEVRO CORP. (NVRO) for Q1 2020, worth a combined $3.38B — down 11% from $3.81B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of NVRO and 31 opened new positions — a net loss of 6 holders — while 65 trimmed existing stakes and 67 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $238M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $67.8M sold.
- 182 institutional investors held NEVRO CORP. (NVRO) as of Q1 2020, down from 191 in Q4 2019.
- Funds reported $3.38B of NEVRO CORP. stock for Q1 2020, down 11% quarter-over-quarter.
- 31 funds opened new NEVRO CORP. positions in Q1 2020 and 37 closed out, a net change of -6 holders.
- The largest NEVRO CORP. buyer in Q1 2020 was T. Rowe Price Associates, an estimated $238M added.
- The largest NEVRO CORP. seller in Q1 2020 was PFM Health Sciences, an estimated $67.8M sold.
Based on aggregated 13F filings for Q1 2020.